Kolexia
Ricci Francesco Oncologie médicale
Ricci Francesco
Oncologie médicale
Scp Drs Franck Dudouet Et Autres, Oncorad Garonne
Quint-Fonsegrives, France
112 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de la prostate Tumeurs du sein triple-négatives Métastase tumorale Tumeurs prostatiques résistantes à la castration Hypertension artérielle Carcinomes Protéinurie Cellules tumorales circulantes

Collaborateurs

Voir plus
Loirat Delphine
Loirat Delphine
Clcc Institut Curie, Paris, France
Le Tourneau Christophe
Le Tourneau Christophe
Clcc Institut Curie, Paris, France
Assaf Elias
Assaf Elias
Hôpital Henri Mondor, Créteil, France
Kokorian Romain
Kokorian Romain
Cabinet libéral, Rouen, France

Industries

Voir plus
P\S\L Group Services
417 collaboration(s)
Dernière en 2023
A+A
278 collaboration(s)
Dernière en 2023
IQVIA
142 collaboration(s)
Dernière en 2023
M3 Global Research Ltd
125 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Essai Clinique (Lilly)   18 mars 2024
SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control
Essai Clinique (Institut Curie)   15 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
ALCINA: Analysis of Circulating Tumor Markers in the Blood
Essai Clinique (Institut Curie)   01 février 2024
RadioPARP: A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease
Essai Clinique (AstraZeneca)   29 janvier 2024
GIG-T: Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors
Essai Clinique (Gustave-Roussy)   18 octobre 2023
A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer: Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer : a Single-arm, Open-label, Ahead Study
Essai Clinique (Henan Cancer Hospital)   22 septembre 2023
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   04 novembre 2022
SOPHIA: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Essai Clinique (MacroGenics)   28 octobre 2022
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
European urology   13 octobre 2022